Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
53 hedge funds and large institutions have $53.6M invested in Novelion Therapeutics Inc. Common Shares in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 21 closing their positions.
1% more capital invested
Capital invested by funds: $53.1M → $53.6M (+$503K)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
22% less funds holding
Funds holding: 68 → 53 (-15)
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
71% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 21
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $110K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$1.26M |
| 2 |
Millennium Management
New York
|
+$1.19M |
| 3 |
Goldman Sachs
New York
|
+$831K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$296K |
| 5 |
ECM
Element Capital Management
New York
|
+$247K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.56M |
| 2 |
State Street
Boston,
Massachusetts
|
-$768K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$465K |
| 4 |
O
OrbiMed
New York
|
-$350K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$269K |
NVLN Hedge Fund Activity: Q2 2018 in Review
53 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q2 2018, worth a combined $53.6M — up 0.95% from $53.1M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of NVLN and 6 opened new positions — a net loss of 15 holders — while 15 trimmed existing stakes and 9 added.
The largest buyer was Healthcare Value Capital, adding an estimated $1.26M. The largest seller was BlackRock, cutting an estimated $2.56M.
- 53 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q2 2018, down from 68 in Q1 2018.
- Funds reported $53.6M of Novelion Therapeutics Inc. Common Shares stock for Q2 2018, up 0.95% quarter-over-quarter.
- 6 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q2 2018 and 21 closed out, a net change of -15 holders.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q2 2018 was Healthcare Value Capital, an estimated $1.26M added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q2 2018 was BlackRock, an estimated $2.56M sold.
Based on aggregated 13F filings for Q2 2018.